Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature 462, 104-107 (5 November 2009) | doi:10.1038/nature08462; Received 16 April 2009; Accepted 24 August 2009; Published online 21 October 2009
Open Innovation Challenges
-
Methods to Analyze Consumer Emotions
The Seeker is looking for methods to analyze consumer emotions. This Challenge requires only a writ...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
nature jobs
Senior Manager-Pharma / CRO-Strategic Sourcing
- Varda Biotech
- Mumbai India
Junior Research Groups (W1 / W2)
- Cluster of Excellence "Multimodal Computing and Interaction"
- Saarbruecken Germany
Requirement for NF-
B signalling in a mouse model of lung adenocarcinoma
Etienne Meylan1, Alison L. Dooley1, David M. Feldser1, Lynn Shen1, Erin Turk1, Chensi Ouyang1 & Tyler Jacks1
- Koch Institute for Integrative Cancer Research, and Department of Biology, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
Correspondence to: Tyler Jacks1 Correspondence and requests for materials should be addressed to T.J. (Email: tjacks@mit.edu).
Abstract
NF-
B transcription factors function as crucial regulators of inflammatory and immune responses as well as of cell survival1. They have also been implicated in cellular transformation and tumorigenesis2, 3, 4, 5, 6. However, despite extensive biochemical characterization of NF-
B signalling during the past twenty years, the requirement for NF-
B in tumour development in vivo, particularly in solid tumours, is not completely understood. Here we show that the NF-
B pathway is required for the development of tumours in a mouse model of lung adenocarcinoma. Concomitant loss of p53 (also known as Trp53) and expression of oncogenic Kras(G12D) resulted in NF-
B activation in primary mouse embryonic fibroblasts. Conversely, in lung tumour cell lines expressing Kras(G12D) and lacking p53, p53 restoration led to NF-
B inhibition. Furthermore, the inhibition of NF-
B signalling induced apoptosis in p53-null lung cancer cell lines. Inhibition of the pathway in lung tumours in vivo, from the time of tumour initiation or after tumour progression, resulted in significantly reduced tumour development. Together, these results indicate a critical function for NF-
B signalling in lung tumour development and, further, that this requirement depends on p53 status. These findings also provide support for the development of NF-
B inhibitory drugs as targeted therapies for the treatment of patients with defined mutations in Kras and p53.
- Koch Institute for Integrative Cancer Research, and Department of Biology, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
Correspondence to: Tyler Jacks1 Correspondence and requests for materials should be addressed to T.J. (Email: tjacks@mit.edu).
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature Letters to Editor (05 Nov 2009)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine Letter (01 Dec 2008)
Modelling Myc inhibition as a cancer therapyNature Letters to Editor (02 Oct 2008)
A spatially and temporally restricted mouse model of soft tissue sarcomaNature Medicine Technical Report (01 Aug 2007)
Colorectal cancer cells with the BRAF V600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIMOncogene Original Article
See all 6 matches for Research
